San Francisco Bay Area based Quellthera is addressing the growing threat of antibiotic resistant disease with EpiQuell, a novel concept in anti-infectives that harnesses the plant kingdom’s evolution-proven ability to control bacterial behavior. Antibiotic approaches to killing bacteria tend to promote increasingly resistant survivors. By efficiently suppressing bacterial virulence while reducing host vulnerability, Epiquell will give physicians new first-line therapies and preventive measures that circumvent antibiotic resistance.
More importantly, EpiQuell may be able to slow, if not reverse, the emergence of drug-resistant superbugs that today threaten the health of future generations.
Quellthera is a licensed subsidiary of LiveLeaf, Inc.